There were 1,849 press releases posted in the last 24 hours and 442,501 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
AffaMed Therapeutics Receives NMPA Approval to Initiate Phase III Clinical Trial in China with Herceptin® (Trastuzumab) Biosimilar Candidate AMT901

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image